BIOEOS LIMITED

Company Registration Number:
05175852 (England and Wales)

Unaudited statutory accounts for the year ended 31 January 2026

Period of accounts

Start date: 1 February 2025

End date: 31 January 2026

BIOEOS LIMITED

Contents of the Financial Statements

for the Period Ended 31 January 2026

Directors report
Balance sheet
Additional notes
Balance sheet notes

BIOEOS LIMITED

Directors' report period ended 31 January 2026

The directors present their report with the financial statements of the company for the period ended 31 January 2026

Principal activities of the company

The Company is principally engaged in research into and commercial development of immune-modulators.



Directors

The directors shown below have held office during the whole of the period from
1 February 2025 to 31 January 2026

Dr O A Bottasso
Mrs C A Stanford
Professor A G Dalgleish
Mrs N S Norman


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
21 October 2026

And signed on behalf of the board by:
Name: Professor A G Dalgleish
Status: Director

BIOEOS LIMITED

Balance sheet

As at 31 January 2026

Notes 2026 2025


£

£
Fixed assets
Intangible assets: 3 500 0
Tangible assets: 4 2,320 0
Total fixed assets: 2,820 0
Current assets
Debtors:   0 0
Cash at bank and in hand: 6,280 5,135
Total current assets: 6,280 5,135
Creditors: amounts falling due within one year: 5 ( 58,576 ) ( 42,397 )
Net current assets (liabilities): (52,296) (37,262)
Total assets less current liabilities: (49,476) ( 37,262)
Provision for liabilities: 0 0
Total net assets (liabilities): (49,476) (37,262)
Capital and reserves
Called up share capital: 1,505 1,505
Share premium account: 111,511 111,511
Profit and loss account: (162,492 ) (150,278 )
Total Shareholders' funds: ( 49,476 ) (37,262)

The notes form part of these financial statements

BIOEOS LIMITED

Balance sheet statements

For the year ending 31 January 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 21 October 2026
and signed on behalf of the board by:

Name: Mrs N S Norman
Status: Director

The notes form part of these financial statements

BIOEOS LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover represents the value of services carried out and goods sold, up to the balance sheet date. Turnover relating to the value of services carried out and goods sold is recognised when substantively all the risks and rewards in connection with the goods and services have been passed to the buyer. This is usually when the goods or services are delivered.

    Tangible fixed assets depreciation policy

    Tangible fixed assets are stated at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Plant and Machinery, etc - 20% on straight line basis Computer Equipment - 33.33% on straight line basis

    Intangible fixed assets amortisation policy

    Intangible fixed assets including BIOEOS website, trade name and goodwill are reviewed for impairment where circumstances indicate that the carrying value of an asset may not be fully recoverable.

    Other accounting policies

    Taxation: Taxation represents the sum of tax currently payable and deferred tax. Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Debtors and Creditors Receivable/Payable Within One Year: Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in administrative expenses. Research and Development: Expenditure on research and development is written off in the period in which it is incurred.

BIOEOS LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

  • 2. Employees

    2026 2025
    Average number of employees during the period 4 4

BIOEOS LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

3. Intangible assets

Goodwill Other Total
Cost £ £ £
At 1 February 2025 0 0
Additions 500 500
Disposals
Revaluations
Transfers
At 31 January 2026 500 500
Amortisation
At 1 February 2025 0 0
Charge for year 0 0
On disposals
Other adjustments
At 31 January 2026 0 0
Net book value
At 31 January 2026 500 500
At 31 January 2025 0 0

BIOEOS LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

4. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 February 2025 392 100 492
Additions 2,900 2,900
Disposals
Revaluations
Transfers
At 31 January 2026 3,292 100 3,392
Depreciation
At 1 February 2025 392 100 492
Charge for year 580 580
On disposals
Other adjustments
At 31 January 2026 972 100 1,072
Net book value
At 31 January 2026 2,320 0 2,320
At 31 January 2025 0 0 0

BIOEOS LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

5. Creditors: amounts falling due within one year note

2026 2025
£ £
Trade creditors 3,387 0
Other creditors 55,189 42,397
Total 58,576 42,397